Amalgamation of Gujarat Themis Biosyn with Themis Medicare
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
The Scheme is subject to approval of the secured creditors and shareholders of TML and GTBL
New research labs and process development services to enable next generation therapeutics
Bringing a new drug to market takes about 10 years and requires an investment of approximately $1 billion
Launch of new product range aligns with strategy to diversify into emerging applications with high growth potential
The GMP inspection assessed mammalian and microbial drug substance manufacturing facility sections
He specializes in financial planning, audit, compliance and ERP implementation, with extensive experience in leading automation and risk management projects
The inspection scope had included six separate Biologics manufacturing units comprising of four Drug Substance and two Drug Product manufacturing plants
Commercial license to Synaffix technologies follows a series of successful initial preclinical proof of concept studies
Partnership to Combine AbbVie's Oncology Expertise with EvolveImmune's Proprietary EVOLVE T-Cell Engager Platform to Develop Novel Multispecific Therapeutic Antibodies for Cancer
Subscribe To Our Newsletter & Stay Updated